Given the pivotal role of the NF-κB signaling pathway in pathological cardiac hypertrophy, identifying novel drugs that can not only inhibit Ang II/AT1R signaling but also prevent adverse effects associated with NF-κB signaling activation may be critical. The gene discussed is NFKB1; the disease is cardiac hypertrophy.